Tumor microenvironment regulation - enhanced radio - immunotherapy

Yu, Xueping; Wang, Xiupeng; Sun, Lue; Yamazaki, Atsushi; Li, Xia

doi:10.1016/j.bioadv.2022.212867

Cited by 9 publications

(5 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The above findings highlight a potential strategy for the use of SM NPs to simultaneously inhibit tumor growth and metastasis by regulating the TME and immune response through combined radiotherapy and immunotherapy with increased efficacy. 76 3.6.2. MnO 2 -Based Nanomaterials for Photoimmunotherapy of Tumors.…”

Section: Mno 2 -Based Nanomaterials For Radiotherapymentioning

confidence: 99%

“…In addition, SM NPs induced an increase in intracellular O 2 and ROS levels by reacting with H 2 O 2 and GSH, thereby exerting a regulatory effect on the TME. The above findings highlight a potential strategy for the use of SM NPs to simultaneously inhibit tumor growth and metastasis by regulating the TME and immune response through combined radiotherapy and immunotherapy with increased efficacy …”

Section: Application Of Mno2-based Nanomaterials For Tumor Therapymentioning

confidence: 99%

See 1 more Smart Citation

Manganese Dioxide-Based Nanomaterials for Medical Applications

Jiang,

Zhao,

Zhang

2024

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Manganese dioxide (MnO 2 ) nanomaterials can react with trace hydrogen peroxide (H 2 O 2 ) to produce paramagnetic manganese (Mn 2+ ) and oxygen (O 2 ), which can be used for magnetic resonance imaging and alleviate the hypoxic environment of tumors, respectively. MnO 2 nanomaterials also can oxidize glutathione (GSH) to produce oxidized glutathione (GSSG) to break the balance of intracellular redox reactions. As a consequence of the sensitivity of the tumor microenvironment to MnO 2 -based nanomaterials, these materials can be used as multifunctional diagnostic and therapeutic platforms for tumor imaging and treatment. Importantly, when MnO 2 nanomaterials are implanted along with other therapeutics, synergetic tumor therapy can be achieved. In addition to tumor treatment, MnO 2 -based nanomaterials display promising prospects for tissue repair, organ protection, and the treatment of other diseases. Herein, we provide a thorough review of recent progress in the use of MnO 2 -based nanomaterials for biomedical applications, which may be helpful for the design and clinical translation of nextgeneration MnO 2 nanomaterials.

show abstract

Section: Mno 2 -Based Nanomaterials For Radiotherapymentioning

confidence: 99%

Section: Application Of Mno2-based Nanomaterials For Tumor Therapymentioning

confidence: 99%

Manganese Dioxide-Based Nanomaterials for Medical Applications

Jiang,

Zhao,

Zhang

2024

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

show abstract

“…[ 88 , 89 ] In the presence of radiation that can facilitate the release of endogenous antigens, anti-CTLA-4 loaded silica nanoparticles also managed to inhibit the growth of primary tumors and prevent the formation of distant metastases. [ 90 ]…”

Section: Nanomaterials-based In Situ Cancer Vaccinesmentioning

confidence: 99%

Biomaterial‐Based In Situ Cancer Vaccines

Yang

Wang

2023

Advanced Materials

View full text Add to dashboard Cite

Cancer immunotherapies have reshaped the paradigm for cancer treatment over the past decade. Among them, therapeutic cancer vaccines that aim to modulate antigen‐presenting cells and subsequent T cell priming processes are among the first FDA‐approved cancer immunotherapies. However, despite showing benign safety profiles and the capability to generate antigen‐specific humoral and cellular responses, cancer vaccines have been limited by the modest therapeutic efficacy, especially for immunologically cold solid tumors. One key challenge lies in the identification of tumor‐specific antigens, which involves a costly and lengthy process of tumor cell isolation, DNA/RNA extraction, sequencing, mutation analysis, epitope prediction, peptide synthesis, and antigen screening. To address these issues, in situ cancer vaccines have been actively pursued to generate endogenous antigens directly from tumors and utilize the generated tumor antigens to elicit potent cytotoxic T lymphocyte (CTL) response. Biomaterials‐based in situ cancer vaccines, in particular, have achieved significant progress by taking advantage of biomaterials that can synergize antigens and adjuvants, troubleshoot delivery issues, home, and manipulate immune cells in situ. This review will provide an overview of biomaterials‐based in situ cancer vaccines, either living or artificial materials, under development or in the clinic, and discuss the design criteria for in situ cancer vaccines.

show abstract

“…Xu et al developed black-pore silicon NPs as a photothermal agent and adjuvant for anti-tumor immunotherapy based on photothermal therapy (PTT); combined with DOX and CpG, they helped to inhibit tumor growth and reduced side effects [ 87 ]. Yu et al used TME regulation SiO 2 @MnO to prepare NPs for combined radiotherapy and immunotherapy, demonstrating their regulatory effect on TME and immune response, and inhibitory effect on tumor growth and metastasis [ 88 ]. Silicon NPs have great potential in drug delivery and immune response in tumor therapy, with promise of even greater possibilities in the future.…”

Section: Biomaterials Used In Tumor Immunotherapymentioning

confidence: 99%

Emerging biomaterials for tumor immunotherapy

et al. 2023

View full text Add to dashboard Cite

Background The immune system interacts with cancer cells in various intricate ways that can protect the individual from overproliferation of cancer cells; however, these interactions can also lead to malignancy. There has been a dramatic increase in the application of cancer immunotherapy in the last decade. However, low immunogenicity, poor specificity, weak presentation efficiency, and off-target side effects still limit its widespread application. Fortunately, advanced biomaterials effectively contribute immunotherapy and play an important role in cancer treatment, making it a research hotspot in the biomedical field. Main body This review discusses immunotherapies and the development of related biomaterials for application in the field. The review first summarizes the various types of tumor immunotherapy applicable in clinical practice as well as their underlying mechanisms. Further, it focuses on the types of biomaterials applied in immunotherapy and related research on metal nanomaterials, silicon nanoparticles, carbon nanotubes, polymer nanoparticles, and cell membrane nanocarriers. Moreover, we introduce the preparation and processing technologies of these biomaterials (liposomes, microspheres, microneedles, and hydrogels) and summarize their mechanisms when applied to tumor immunotherapy. Finally, we discuss future advancements and shortcomings related to the application of biomaterials in tumor immunotherapy. Conclusion Research on biomaterial-based tumor immunotherapy is booming; however, several challenges remain to be overcome to transition from experimental research to clinical application. Biomaterials have been optimized continuously and nanotechnology has achieved continuous progression, ensuring the development of more efficient biomaterials, thereby providing a platform and opportunity for breakthroughs in tumor immunotherapy. Graphical Abstract

show abstract

Tumor microenvironment regulation - enhanced radio - immunotherapy

Cited by 9 publications

References 78 publications

Manganese Dioxide-Based Nanomaterials for Medical Applications

Manganese Dioxide-Based Nanomaterials for Medical Applications

Biomaterial‐Based In Situ Cancer Vaccines

Emerging biomaterials for tumor immunotherapy

Contact Info

Product

Resources

About